Basic Information


GTO ID GTC0376
Trial ID NCT03170141
Disease Brain Glioblastoma Multiforme
Altered gene GD2
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment GD2 CAR-T cells
PhasePhase1
Recruitment statusRecruiting
TitleImmunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
Year2017
CountryChina
Company sponsorShenzhen Geno-Immune Medical Institute
Other ID(s)GIMI-IRB-17003
Vector information
Vectorlentivirus
ConstructscFv-CD28-4-1BB-CD3ζ
Vector typeNHP/TYF lentivector system
Transgene/Inserted geneCD28 transmembrane and cytoplasmic domains; co-stimulatory 4-1BB intracellular TRAF binding domain; CD3z chain intracellular domain; inducible suicide caspase 9 gene
Viral genome modificationThe DNA sequences of GD2 scFv were cloned into a pTYF lentiviral vector, followed by the lentiviral particle package. The GD2 CAR sequence was constructed with lentiviral 4SCAR.
Vector production methodAutologous GD2-specific 4SCAR-T cells were manufactured from 2 to 5 × 109 lymphocytes in the peripheral blood.Peripheral blood buffy coats were collected from patients and peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque plus (GE Healthcare). Lymphocytes were activated using phytohemagglutinin (5 µg/mL) for 2-3 days, after which the cells were maintained in TexMACS medium supplemented with human IL-2 (40 U/mL), IL-7 (20 U/mL), and IL-15 (10 U/mL). Activated T cells were transduced with GD2-specific 4SCAR vectors and expanded for six-ten days.
Additional featureiCasp9

Clinical Result

Cohort 1
Administration route intravenous infusion|intravenous combined intracavitary administration
Dosage 0.5E5~2.5E7 cells/kg
Pts 8
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome 4/8(PR); 1/8(SD); 3/8(PD). The overall survival was 10 months after the infusion.
References PMID: 36617554

Relationship Graph

Overview of Knowledge Graph